Valuation: ThermoGenesis Holdings, Inc.

Capitalization 11.09K 9.48K 8.74K 8.25K 15.32K 1.04M 15.71K 102K 40.24K 496K 41.63K 40.75K 1.77M P/E ratio 2022
-0.16x
P/E ratio 2023 -0.08x
Enterprise value 9.29M 7.94M 7.32M 6.91M 12.84M 870M 13.16M 85.74M 33.71M 416M 34.88M 34.14M 1.48B EV / Sales 2022
0.97x
EV / Sales 2023 1.18x
Free-Float
71.98%
Yield 2022 *
-
Yield 2023 -
1 month 0
Extreme 0.0001
0
Current year 0
Extreme 0
0
1 year 0
Extreme 0
0
3 years 0
Extreme 0
2.98
5 years 0
Extreme 0
142.2
10 years 0
Extreme 0
3,325.5
Manager TitleAgeSince
Chief Executive Officer 55 2016-11-02
Investor Relations Contact - -
Director TitleAgeSince
Chairman 55 2016-11-02
Director/Board Member - 2023-07-13
Change 5d. change 1-year change 3-years change Capi.($)
0.00%0.00% - -100.00% 1.58K
+1.58%+6.26%+29.18%-14.91% 26.83B
+1.28%+1.49%+8.99%-6.67% 6.89B
-3.28%+10.33%+20.61%+35.90% 2.7B
-0.30%-0.66%-6.53%-66.77% 2.14B
+0.76%+2.57%+39.85%+47.40% 1.93B
-0.88%+3.34%+29.00%+26.55% 1.78B
+0.09%+2.81%+139.26%+63.00% 1.64B
+3.86%+8.49%+29.37%+65.05% 1.15B
+0.44%+4.53%-42.31%-49.84% 895M
Average +0.39%+3.65%+27.49%-0.03% 4.6B
Weighted average by Cap. +1.06%+4.07%+26.97%-4.77%

Financials

2022 2023
Net sales 10.48M 8.96M 8.26M 7.79M 14.48M 982M 14.85M 96.72M 38.02M 469M 39.34M 38.51M 1.67B 9.44M 8.07M 7.44M 7.02M 13.05M 884M 13.38M 87.14M 34.26M 422M 35.45M 34.69M 1.51B
Net income -11.27M -9.63M -8.88M -8.38M -15.57M -1.06B -15.96M -104M -40.88M -504M -42.3M -41.4M -1.8B -17.98M -15.36M -14.16M -13.36M -24.83M -1.68B -25.46M -166M -65.2M -804M -67.46M -66.03M -2.87B
Net Debt 6.89M 5.88M 5.43M 5.12M 9.51M 645M 9.76M 63.55M 24.98M 308M 25.85M 25.3M 1.1B 9.28M 7.93M 7.31M 6.9M 12.82M 869M 13.15M 85.64M 33.67M 415M 34.83M 34.1M 1.48B
Logo ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. The Company provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, the PXP platform for point-of-care cell-based therapies and X-Series products for cell processing services. Its product lines include Clinical Bio-Banking Applications, Point-of-Care Applications and Cell Processing. Its Clinical Bio-Banking Applications include AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Its Point-of-Care Applications include PXP Point-of-Care System, and PXP-1000 System. Its Cell Processing includes X-Series Products for general laboratory use: X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The Company markets and sells its medical device products through independent distributors.
Employees
25

Quarterly revenue - Rate of surprise